-
公开(公告)号：US20230357386A1
公开(公告)日：2023-11-09
申请号：US18027413
申请日：2021-12-22
发明人： Tomomi KAWAKATSU , Akio YAMADA , Aki NAKATANI , Eiji INOUE
CPC分类号： C07K16/28 , C12N15/63 , C07K2317/565
摘要： Provided is an anti-EphA4 antibody capable of binding to EphA4 and enhancing the cleavage of EphA4, and a pharmaceutical composition comprising the antibody as an active ingredient. The anti-EphA4 antibody comprises a heavy chain comprising a heavy chain CDR1 of SEQ ID NO: 30; a heavy chain CDR2 of SEQ ID NO: 31; and a heavy chain CDR3 of SEQ ID NO: 32; and a light chain comprising a light chain CDR1 of SEQ ID NO: 33; a light chain CDR2 of SEQ ID NO: 34; and a light chain CDR3 of SEQ ID NO: 35, or a heavy chain comprising a heavy chain CDR1 of SEQ ID NO: 42; a heavy chain CDR2 of SEQ ID NO: 31; and a heavy chain CDR3 of SEQ ID NO: 43; and a light chain comprising a light chain CDR1 of SEQ ID NO: 44; a light chain CDR2 of SEQ ID NO: 34; and a light chain CDR3 of SEQ ID NO: 35.
-
公开(公告)号：US20210002378A1
公开(公告)日：2021-01-07
申请号：US16915412
申请日：2020-06-29
发明人： Eiji INOUE , Akio YAMADA , Tomomi KAWAKATSU , Toshio IMAI , Maki DEGUCHI , Aki NAKATANI
摘要： Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient.
A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.-
公开(公告)号：US20210171644A1
公开(公告)日：2021-06-10
申请号：US17145001
申请日：2021-01-08
发明人： Eiji INOUE , Akio YAMADA , Tomomi KAWAKATSU , Toshio IMAI , Maki DEGUCHI , Aki NAKATANI
摘要： Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient.
A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.
-
-
搜索结果
3 条记录 (耗时 0.033 秒)
